Blue Point Capital Partners, in conjunction with its portfolio company, Quality Synthetic Rubber, Inc. (QSR), announced today the acquisition of Wisconsin-based Quadra, Inc. Quadra primarily does business under the brand name Limtech as a leading manufacturer of custom-molded silicone products for the medical, dental, industrial and consumer markets.
CLEVELAND (November 1, 2011) – Blue Point Capital Partners, in conjunction with its portfolio company, Quality Synthetic Rubber, Inc. (QSR), announced today the acquisition of Wisconsin-based Quadra, Inc. Quadra primarily does business under the brand name Limtech as a leading manufacturer of custom-molded silicone products for the medical, dental, industrial and consumer markets.
QSR (www.qsr-inc.com), headquartered in Twinsburg, Ohio, has operations in North America and China and is a leading manufacturer of highly engineered, molded rubber components serving the medical, automotive, heavy transportation and industrial markets. Blue Point invested in QSR from its 2006 vintage fund, Blue Point Capital Partners II, L.P. – a $400 million lower middle market buyout fund.
The acquisition will supplement QSR’s medical subsidiary, Medical Elastomer Development, Inc. (MED), which produces highly precise silicone components such as vessel loops, IV components, catheters, and surgical and sterilization components. Limtech brings added technical abilities, rapid prototyping and added cleanroom capacity to MED’s growing medical business presence.
“A key component of our strategic plan at QSR is to expand its medical business,” said John LeMay, a partner with Blue Point. “Since our acquisition in 2007, QSR has made significant investments to strengthen the MED platform. The acquisition of Limtech further supports our strategy by broadening the Company’s medical product offering and significantly diversifying QSR’s customer base.”
Randy Ross, chief executive officer of QSR, said, “We are enthusiastic about the acquisition of Limtech and anticipate several key benefits for our customers, including faster time to market with new products as a result of incorporating Limtech’s state-of-the-art tooling capabilities, an increased array of production capabilities and a second manufacturing location for medical products.”
Blue Point Capital Partners (www.bluepointcapital.com), with offices in Charlotte, Cleveland, Seattle and Shanghai, is one of the largest and most active resident middle market private equity firms in each of its target markets and focuses principally on investments in manufacturing, distribution and service businesses that primarily address commercial and industrial markets. Blue Point’s presence in the economies of both the United States and China positions the firm to create value by helping its investee firms to globalize. Blue Point has extensive experience in identifying, evaluating and successfully completing a variety of private equity investment transactions, including recapitalizations, management buyouts, corporate divestitures and industry consolidations. The principals of Blue Point have completed over 100 investments with a total transaction value of more than $2 billion.
For more information, contact:
BLUE POINT CAPITAL PARTNERS
Blue Point Capital Partners, LLC
127 Public Square, Suite 5100
Cleveland, OH 44114